Cancer Supportive Care Drugs Market, By Drug Type, By Therapeutic Area, By Distribution, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
Cancer Supportive Care Drugs Market size was valued at USD 21,410.32 Million in 2023, expanding at a CAGR of 2.31% from 2024 to 2032.
The Cancer Supportive Care Drugs market encompasses medications designed to alleviate the side effects of cancer treatments, enhance patients' quality of life, and support overall health during therapy. Increasing cancer incidence and the rise in treatment options are fueling the demand for supportive care drugs, with the American Cancer Society reporting that approximately 1.9 million new cancer cases are expected in the U.S. in 2024. Moreover, the growing awareness of the importance of palliative care is encouraging healthcare providers to focus on managing treatment-related adverse effects such as nausea, pain, and fatigue. However, challenges such as high costs associated with novel drugs and reimbursement issues can restrain market growth. On the other hand, opportunities lie in the development of personalized supportive care therapies and expanding markets in developing regions, where rising healthcare expenditure and access to innovative treatments are increasing. Additionally, collaborations between pharmaceutical companies and healthcare institutions to enhance drug efficacy and patient outcomes represent a promising avenue for market expansion.
Cancer Supportive Care Drugs Market- Market Dynamics
Rising Cancer Incidence Accelerates Growth in the Cancer Supportive Care Drugs Market
The rising incidence of cancer is significantly driving growth in the Cancer Supportive Care Drugs market, as more patients seek therapies to manage treatment-related side effects. According to the World Health Organization (WHO), cancer is currently the second leading cause of death globally, with nearly 10 million fatalities in 2020. This alarming trend has prompted an increased focus on supportive care options to enhance the quality of life for patients undergoing chemotherapy, radiation, and other treatments. For instance, the American Society of Clinical Oncology (ASCO) emphasizes the importance of managing symptoms such as nausea, pain, and fatigue, which are prevalent among cancer patients. Additionally, organizations like the National Cancer Institute are advocating for research into novel supportive care drugs, further amplifying the demand for effective treatments. As healthcare providers expand their focus on comprehensive cancer care, the market for supportive therapies is expected to flourish, reflecting a critical need to improve patient outcomes in this challenging health landscape.
Cancer Supportive Care Drugs Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 2.31% over the forecast period (2024-2032)
Based on Drug Type segmentation, Anti-emetics was predicted to show maximum market share in the year 2023
Based on Therapeutic Area segmentation, Chemotherapy-Induced Nausea, and Vomiting was the leading type in 2023
Based on distribution segmentation, Hospital Pharmacies was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
Cancer Supportive Care Drugs Market- Segmentation Analysis:
The Global Cancer Supportive Care Drugs Market is segmented on the basis of Drug Type, Therapeutic Area, Distribution, End-User, and Region.
The market is divided into four categories based on Drug Type: Erythropoiesis-Stimulating Agents, Granulocyte Colony-Stimulating Factors (G-CSFs), Anti-emetics, and Bisphosphonates. Anti-emetics are predicted to show maximum market share due to their essential role in managing chemotherapy-induced nausea and vomiting. Erythropoiesis-stimulating agents follow closely, as they help combat anemia in cancer patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are also significant, supporting neutrophil recovery after chemotherapy. Bisphosphonates, while important for bone health, hold a relatively lower market share compared to the other drug types.
The market is divided into three categories based on Therapeutic Area: Chemotherapy-Induced Nausea and Vomiting, Chemotherapy-Induced Anemia, and Neutropenia. Chemotherapy-induced nausea and Vomiting is the leading therapeutic area, primarily due to the high prevalence of these side effects among cancer patients undergoing treatment. Following this, Chemotherapy-Induced Anemia ranks second, as many patients experience low red blood cell counts due to their therapies. Neutropenia, while also critical, holds a smaller share of the market compared to the other therapeutic areas.
Cancer Supportive Care Drugs Market- Geographical Insights
The geographical landscape of the Cancer Supportive Care Drugs market is characterized by significant growth in North America, particularly in the United States, where a high incidence of cancer and advanced healthcare infrastructure drive demand. According to the American Cancer Society, about 1.9 million new cancer cases were expected in the U.S. in 2024, leading to increased utilization of supportive care drugs. Europe follows closely, with countries like Germany and France investing in innovative treatment options and research initiatives aimed at improving cancer care. Additionally, Asia-Pacific is emerging as a notable region for market expansion, driven by rising healthcare expenditures and increasing awareness of cancer treatment options in countries like China and India. The World Health Organization has emphasized the need for enhanced cancer care in developing regions, further propelling growth in supportive care solutions. As a result, companies are focusing on regional partnerships and tailored marketing strategies to meet the specific needs of these diverse markets.
Cancer Supportive Care Drugs Market- Competitive Landscape:
The competitive landscape of the Cancer Supportive Care Drugs market is marked by the presence of several key players that are actively engaged in developing innovative therapies to meet the growing demand for supportive care. Leading companies such as Amgen, Roche, and Merck are focusing on research and development to enhance their product offerings, particularly in the areas of anti-emetics and granulocyte colony-stimulating factors (G-CSFs). For instance, Amgen's Neulasta (pegfilgrastim) has been a frontrunner in the G-CSF segment, helping to reduce the risk of infection in chemotherapy patients. Collaborations and partnerships are also common, as seen with Bristol-Myers Squibb's alliance with various healthcare institutions to advance research in supportive care. Furthermore, recent acquisitions, such as Pfizer's purchase of Array BioPharma, have strengthened companies' portfolios in cancer therapies, including supportive care drugs. As companies continue to innovate and expand their reach, the competition in this market remains robust, driving advancements that improve patient outcomes in cancer care.
Recent Developments:
In January 2023, Helsinn Healthcare SA and Immedica Pharma AB signed an exclusive long-term agreement to commercialize two cancer-supportive care products, Akynzeo and Aloxi, in key European markets, targeting the prevention of chemotherapy-induced nausea and vomiting.
In August 2024, the FDA approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor, for treating patients with NTRK-positive locally advanced or metastatic solid tumors, enhancing options in cancer supportive care and targeted therapies.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Amgen Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche AG
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Roche Holding AG
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Others
GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
Erythropoiesis-Stimulating Agents
Granulocyte Colony-Stimulating Factors (G-CSFs)
Anti-emetics
Bisphosphonates
GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032
Chemotherapy-Induced Nausea and Vomiting
Chemotherapy-Induced Anemia
Neutropenia
GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
Pediatric Patients
Adult Patients
Geriatric Patients
GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA
Table of Contents
1. Cancer Supportive Care Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Cancer Supportive Care Drugs Market Snippet by Drug Type
2.1.2. Cancer Supportive Care Drugs Market Snippet by Therapeutic Area
2.1.3. Cancer Supportive Care Drugs Market Snippet by Distribution
2.1.4. Cancer Supportive Care Drugs Market Snippet by End-User
2.1.5. Cancer Supportive Care Drugs Market Snippet by Country
2.1.6. Cancer Supportive Care Drugs Market Snippet by Region
2.2. Competitive Insights
3. Cancer Supportive Care Drugs Key Market Trends
3.1. Cancer Supportive Care Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Cancer Supportive Care Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Cancer Supportive Care Drugs Market Opportunities
3.4. Cancer Supportive Care Drugs Market Future Trends
4. Cancer Supportive Care Drugs Industry Study
4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Cancer Supportive Care Drugs Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Cancer Supportive Care Drugs Market Landscape
6.1. Cancer Supportive Care Drugs Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players' Analysis
6.2.2. Emerging Players' Analysis
7. Cancer Supportive Care Drugs Market - By Drug Type
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)